Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018

  • ID: 4482731
  • Report
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amryt Pharma plc
  • Ipsen SA
  • Zucara Therapeutics Inc
  • MORE
Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018

Summary:

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney.

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 4 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Hormonal Disorders, Metabolic Disorders, Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ophthalmology and Women's Health which include indications Acromegaly, Neuroendocrine Tumors, Diabetic Retinopathy, Pituitary ACTH Hypersecretion (Cushing Disease), Age Related Macular Degeneration, Chronic Pain, Gastric Motility Disorder, Gastrointestinal Tumor, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Neuropathic Pain, Pancreatic Tumor, Pituitary Tumor, Polycystic Kidney Disease, Type 2 Diabetes and Women Infertility.

The latest report Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H1 2018, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amryt Pharma plc
  • Ipsen SA
  • Zucara Therapeutics Inc
  • MORE
Introduction

Report Coverage

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development

Amryt Pharma plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Takeda Pharmaceutical Co Ltd

Zucara Therapeutics Inc

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIM-23627 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Edotreotide Labeled Yttrium 90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRL-2903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 for Neuroendocrine Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumors (NETs)

Jan 15, 2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018

Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

Sep 21, 2017: JDRF Funds Zucara Therapeutics' Approach to Preventing Hypoglycemia in People with Type 1 Diabetes

Sep 18, 2017: U.S. FDA Approves New Indication for Ipsen’s Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

Sep 04, 2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress

Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN0

Jul 03, 2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

Jun 01, 2017: Ipsen To Present New Data of Lanreotide at ASCO

Mar 09, 2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP

Dec 02, 2016: Amryt Pharma provides update on AP-

Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly

Sep 30, 2016: Ipsen Biopharmaceuticals Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society Symposium

Sep 27, 2016: Ipsen Announces Data Presentations of Lanreotide (Somatuline Autogel) at the European Society for Medical Oncology (ESMO) 2016 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amryt Pharma plc, H1 2018

Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Pipeline by Ipsen SA, H1 2018

Pipeline by Progenics Pharmaceuticals Inc, H1 2018

Pipeline by Strongbridge Biopharma plc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Pipeline by Zucara Therapeutics Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amryt Pharma plc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Ipsen SA
  • Progenics Pharmaceuticals Inc
  • Strongbridge Biopharma plc
  • Takeda Pharmaceutical Co Ltd
  • Zucara Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll